Cosmetic cross-reference

Ubidecarenone

CAS 303-98-0

Ubidecarenone (CAS 303-98-0) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 4,018 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

4,018

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Ubidecarenone

CAS Number

303-98-0

UNII

EJ27X76M46

InChIKey

ACTIUHUUMQJHFO-UPTCCGCDSA-N

ChEMBL ID

CHEMBL454801

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL454801 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	30000 nM	66	-
-	Potency	326.8 nM	2	-
-	IC50	19976.309999999998 nM	1	-
-	GI50	220000 nM	1	-

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Muscle spasticity	208	453.608	10028335
Ear pain	226	423.411	10014020
Night sweats	229	334.004	10029410
Body temperature increased	211	326.714	10005911
Respiratory disorder	216	326.313	10038683
Insomnia	366	200.932	10022437
Back pain	388	185.503	10003988
Peripheral swelling	359	175.228	10048959
Sinusitis	310	172.858	10040753
Asthenia	503	164.412	10003549
Urticaria	254	134.515	10046735
Lower respiratory tract infection	209	125.438	10024968
Abdominal pain upper	267	113.472	10000087
Pruritus	373	99.273	10037087
Diarrhoea	643	96.425	10012735
Toxicity to various agents	20	88.152	10070863
Headache	501	81.832	10019211
Vaginal flatulence	31	72.919	10064227
Fatigue	672	72.239	10016256
Joint swelling	279	65.255	10023232
Rash	439	55.49	10037844
Pain	505	53.845	10033371
Completed suicide	7	52.908	10010144
Vaginal discharge	34	51.907	10046901
Female genital tract fistula	31	50.09	10061149
Proctitis	32	49.69	10036774
Radiculopathy	36	49.576	10037779
Constipation	238	49.093	10010774
Acute kidney injury	69	47.484	10069339
Full blood count decreased	61	45.528	10017413
General physical health deterioration	26	42.488	10049438
Drug abuse	3	41.938	10013654
COVID-19	7	40.892	10084268
Exposure during pregnancy	5	40.158	10073513
Treatment failure	18	39.723	10066901
Maternal exposure during pregnancy	15	36.994	10071408
Overdose	13	35.805	10033295
Chronic sinusitis	34	35.064	10009137
Muscle spasms	151	32.064	10028334
Paraesthesia oral	39	32.004	10057372
Blindness cortical	12	31.245	10005177
C-reactive protein increased	6	30.685	10006825
Myalgia	151	30.399	10028411
Dyspepsia	106	30.126	10013946
Therapy cessation	53	29.168	10065154
Procedural pain	38	27.425	10064882
Systemic lupus erythematosus	21	27.171	10042945
Feeling abnormal	133	26.136	10016322
Incorrect route of product administration	50	25.383	10081202
Drug interaction	70	25.338	10013710

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
UBIDECARENONE	21406	SU	MTHSPL
ubidecarenone	21406	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ubidecarenone used for in pharmaceutical contexts?

Ubidecarenone (CAS 303-98-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ubidecarenone?

Ubidecarenone has 4,018 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Muscle spasticity, Ear pain, Night sweats, Body temperature increased, Respiratory disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ubidecarenone also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ubiquinone with EU status "permitted".

What clinical phase is Ubidecarenone in?

Ubidecarenone is rendered with ChEMBL max phase 3.